Raymond James Financial Services Advisors Inc. Sells 9,727 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX)

Raymond James Financial Services Advisors Inc. cut its holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX) by 22.4% in the fourth quarter, HoldingsChannel reports. The firm owned 33,719 shares of the company’s stock after selling 9,727 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in G1 Therapeutics were worth $103,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Creative Financial Designs Inc. ADV boosted its holdings in G1 Therapeutics by 98.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after acquiring an additional 17,475 shares during the period. Algert Global LLC bought a new stake in G1 Therapeutics during the third quarter valued at about $98,000. Curi Wealth Management LLC boosted its holdings in G1 Therapeutics by 17.8% during the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock valued at $102,000 after acquiring an additional 10,700 shares during the period. Acadian Asset Management LLC bought a new stake in G1 Therapeutics during the third quarter valued at about $189,000. Finally, Denali Advisors LLC boosted its holdings in G1 Therapeutics by 121.8% during the third quarter. Denali Advisors LLC now owns 148,800 shares of the company’s stock valued at $214,000 after acquiring an additional 81,700 shares during the period. 24.21% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the transaction, the insider now owns 169,938 shares of the company’s stock, valued at $785,113.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.23% of the company’s stock.

G1 Therapeutics Stock Down 3.3 %

NASDAQ GTHX opened at $3.86 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.45 and a current ratio of 3.87. The firm has a 50-day simple moving average of $3.72 and a 200 day simple moving average of $2.96. G1 Therapeutics, Inc. has a twelve month low of $1.08 and a twelve month high of $5.00. The stock has a market cap of $201.61 million, a PE ratio of -4.06 and a beta of 1.73.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Wednesday, February 28th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative net margin of 58.13% and a negative return on equity of 106.04%. The business had revenue of $14.87 million during the quarter, compared to analysts’ expectations of $12.83 million. During the same quarter last year, the company earned ($0.73) earnings per share. On average, research analysts forecast that G1 Therapeutics, Inc. will post -0.64 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $12.00 price target on shares of G1 Therapeutics in a report on Friday, April 12th. Wedbush reiterated an “outperform” rating and issued a $5.00 target price (up previously from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.